Drugs / Allogeneic Mesenchymal Bone Marrow Cells
Allogeneic Mesenchymal Bone Marrow Cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01771679 | Jul 2015 → Apr 2024 | chronic actinic dermatitis | Stemedica Cell Technologies, Inc. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03925324 | May 2019 → Aug 2021 | intrinsic cardiomyopathy, myocardial ischemia | Medstar Health Research Institute | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT02467387 | Jun 2014 → May 2017 | heart failure | CardioCell LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2020-04-20 | Stemedica Cell Technologies, Inc. | Regulatory FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHN’S HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS stemedica.com ↗
A single patient, emergency Investigational New Drug (IND) use was cleared by the U.S. Food and Drug Administration |
| 2019-10-30 | Stemedica Cell Technologies, Inc. | Results Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke stemedica.com ↗
Intravenous transfusion of low oxygen mesenchymal bone marrow cells in patients with disabling chronic stroke was safe and significantly improved several behavioral measures. |
| 2019-09-30 | Stemedica Cell Technologies, Inc. | Results Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal stemedica.com ↗
Study testing disclosed no safety concerns. |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-04-20 | Stemedica Cell Technologies, Inc. | FIRST COVID-19 PATIENT TREATED UNDER EMERGENCY USE IND AT PROVIDENCE SAINT JOHN’S HEALTH CENTER USING STEMEDICA ISCHEMIA-TOLERANT ALLOGENEIC MESENCHYMAL BONE MARROW CELLS stemedica.com ↗ |
| 2019-10-30 | Stemedica Cell Technologies, Inc. | Stemedica Reports Positive Results from Phase IIa Clinical Trial Using IV Administration of Mesenchymal Stem Cells for Ischemic Stroke stemedica.com ↗ |
| 2019-09-30 | Stemedica Cell Technologies, Inc. | Positive Study Results of Phase IIa Clinical Trial Using Intravenous Administration of Mesenchymal Stem Cells for Ischemic Stroke Published in Peer-Reviewed Stroke Journal stemedica.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Bone Marrow Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01771679 ↗ |
| Known as | aMBMC | “Drug: Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)” NCT02467387 ↗1“Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)” NCT03925324 ↗ |
| Known as | Human Allogeneic Mesenchymal Bone Marrow Cells | “Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)” NCT03925324 ↗ |
| Modality | Cell therapy | “Mesenchymal stem cells (MSCs)” NCT01771679 ↗ |
| Route | Intravenous | “single intravenous infusion” NCT01771679 ↗ |